Immune System Diseases

926 trials 377 recruiting

Filter these 926 trials by phase, country and sponsor.

Open in Search →

Efficacy and safety of the proposed biosimilar PERT-IJS versus EU-Perjeta® along with trastuzumab and chemotherapy (carboplatin and docetaxe… Ended

2023-506163-34-00 Hormone Receptor Negative (HR-ve) Human Epidermal Growt 5
A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants … Ended

2023-510340-20-00 Systemic Lupus Erythematosus 3
Study of IMG-007 in Participants with Moderate to Severe Atopic Dermatitis Ended

2023-505735-13-01 Atopic dermatitis 9
TOFA-PREDICT Ended

2024-510903-12-00 Psoriatic arthritis 6
A controlled phase II clinical trial evaluating the safety and efficacy of myelin peptide-loaded tolDC as treatment for Multiple Sclerosis Ended

2024-512891-37-00 Multiple Sclerosis 4
A Phase 2a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Burfiralimab (hzVSF-v13)… Ended

2023-507944-35-00 rheumatoid arthritis 4
IFM 2020-01 (Isamyp) Efficacity assessment of isatuximab plus pomalidomide and dexamethasone in patients with AL amyloidosis who didn't reac… Ended

2024-513887-25-00 AL Amyloidosis 4
A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoria… Ended

2023-508992-35-00 Plaque Psoriasis 4
Evaluating the efficacy and safety of hyperbaric oxygen therapy as an adjuvant treatment compared to biologic therapy alone in moderate to s… Ended

2023-507450-32-00 Ulcerative colitis 5
Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults with Severe Immunoglobulin E (IgE)-Mediated Food Aller… Ended

2024-511032-27-00 Severe IgE-mediated food allergy 3
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart i… Ended

2024-512986-15-00 Sjögren’s Disease 4
A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma Ended

2023-503348-15-00 Hodgkin lymphoma or non-Hodgkin lymphoma 7
A study evaluating the safety, tolerability, and efficacy of GLPG5101 in adults with treatment-refractory active systemic lupus erythematosu… Ended

2023-504422-19-00 Treatment-refractory active systemic lupus erythematosu 3
A Phase 3, Open-Label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Activity, and Safety of Ravulizumab… Ended

2022-502335-19-00 Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 5